FDA WARNING_LETTER - Cigsweb.com - May 03, 2022

The FDA's Center for Tobacco Products issued a Warning Letter to cigsweb.com on April 26, 2022, following a review of their website, which revealed the sale and distribution of cigarette products to U.S. customers. The FDA determined these products are "tobacco products" under the FD&C Act.

The primary violation identified is the sale of "modified risk tobacco products" without an FDA order, rendering them adulterated under section 902(8) of the FD&C Act. Cigsweb.com explicitly or implicitly represented that their products, including brands like Camel Compact Blue and Marlboro Fine Touch, present lower risks, contain reduced substance levels, or are free of certain substances. Examples of violative claims include "light," "Super Lights," "mild," "low content of tar and nicotine," and "safer smoking technology." Section 911(a) of the FD&C Act prohibits introducing such products into interstate commerce without an FDA order, which requires scientific evidence.

The letter emphasizes the company's responsibility to ensure all tobacco products, labeling, and advertising comply with the FD&C Act and FDA regulations (21 C.F.R. Parts 1140, 1141, and 1143). Failure to comply may result in regulatory actions such as civil money penalties, seizure, or injunction. Imported products appearing adulterated or misbranded may